INmune Bio (INmune Bio) FCF Margin % : -12,146.43% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is INmune Bio FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. INmune Bio's Free Cash Flow for the three months ended in Dec. 2023 was $-3.40 Mil. INmune Bio's Revenue for the three months ended in Dec. 2023 was $0.03 Mil. Therefore, INmune Bio's FCF Margin % for the quarter that ended in Dec. 2023 was -12,146.43%.

As of today, INmune Bio's current FCF Yield % is -5.65%.

The historical rank and industry rank for INmune Bio's FCF Margin % or its related term are showing as below:

INMB' s FCF Margin % Range Over the Past 10 Years
Min: -81300 Med: -15882.2 Max: -6065.78
Current: -7729.03

During the past 8 years, the highest FCF Margin % of INmune Bio was -6065.78%. The lowest was -81300.00%. And the median was -15882.20%.

INMB's FCF Margin % is ranked worse than
90.72% of 1034 companies
in the Biotechnology industry
Industry Median: -148.935 vs INMB: -7729.03

INmune Bio FCF Margin % Historical Data

The historical data trend for INmune Bio's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INmune Bio FCF Margin % Chart

INmune Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-81,300.00

-24,035.36

-6,065.78

-7,729.03

INmune Bio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-5,871.13	-3,002.63	-6,900.00	-9,916.28	-12,146.43

Competitive Comparison of INmune Bio's FCF Margin %

For the Biotechnology subindustry, INmune Bio's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

INmune Bio's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, INmune Bio's FCF Margin % distribution charts can be found below:

* The bar in red indicates where INmune Bio's FCF Margin % falls into.

INmune Bio FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

INmune Bio's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-11.98	/	0.155
	=	-7,729.03 %

INmune Bio's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-3.401	/	0.028
	=	-12,146.43 %

INmune Bio FCF Margin % Related Terms

Thank you for viewing the detailed overview of INmune Bio's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

INmune Bio (INmune Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » INmune Bio Inc (NAS:INMB) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432

Website

https://www.inmunebio.com

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

Executives

Scott Juda	director	325 N. LARCHMONT BLVD, SUITE 375, LOS ANGELES CA 90004
Timothy J Schroeder	director	2690 DEVILS BACKBONE ROAD, CINCINNATI OH 45233
David J Moss	10 percent owner, officer: CFO, Treasurer & Secretary	C/O PEGASI ENERGY RESOURCES CORPORATION, 218 N. BROADWAY, SUITE 204, TYLER TX 75702
Raymond Joseph Tesi	director, 10 percent owner, officer: President & CEO	476 MASSACHUSETTS AVE, UNIT 2, BOSTON MA 02118
Mark William Lowdell	10 percent owner, officer: Chief Scientific Officer	THE OAK, WLX ROAD, BEAUMONT X0 CO16 0AT
Linda F Powers	10 percent owner	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
James Kelly Ganjei	director	10609 RIVER OAKS LANE, POTOMAC MD 20859
Marcia Allen	director	P.O. BOX 399, 2600 W. HOMESTEAD CIRCLE, WILSON WY 83014
Edgardo Jr Baracchini	director	C/O METABASIS THERAPEUTICS, 9390 TOWNE CENTRE DRIVE, BLDG. 300, SAN DIEGO CA 92121
Xencor Inc	10 percent owner	465 N. HALSTEAD ST., SUITE 200, PASADENA CA 91107
David Edmund Szymkowski	director	241 WEST PALM AVENUE, MONROVIA CA 91016